Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double-blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ϵ2-3 as theϵ4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p< 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ϵ2-3 compared with ϵ4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ϵ2-3 andϵ4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.

[1]  J. Hardy,et al.  APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease , 1994, Neuroscience Letters.

[2]  R. Mahley,et al.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.

[3]  L. Schneider,et al.  Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease , 1995 .

[4]  R. Penn,et al.  Neurosurgical horizons in Parkinson's disease , 1993, Neurology.

[5]  S. Gauthier,et al.  Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies , 1994, Annals of neurology.

[6]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[7]  Giovanni B. Frisoni,et al.  Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .

[8]  A. Thomas,et al.  Genesis and evolution of behavioral disorders: from infancy to early adult life. , 1984, The American journal of psychiatry.

[9]  B. Kirkwood,et al.  Vitamin A supplementation in northern Ghana: effects on clinic attendances, hospital admissions, and child mortality , 1993, The Lancet.

[10]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[11]  T. Eisner,et al.  Chemical ecology. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[13]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Schneider,et al.  Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease. , 1989, Psychiatric developments.

[15]  R. Daroff.  A new look and feel , 1996, Neurology.

[16]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[18]  G. Cutter,et al.  Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis , 1995, Annals of neurology.

[19]  M Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[20]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[21]  K E Peace,et al.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Michael V. Cohen,et al.  Ischaemic preconditioning: can the protection be bottled? , 1993, The Lancet.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[24]  J. Poirier.  Apolipoprotein E in animal models of CNS injury and in alzheimer's disease , 1994, Trends in Neurosciences.

[25]  M. Misawa,et al.  The role of dopamine D1-receptors in morphine-induced hyperlocomotion in mice , 1994, Neuroscience Letters.

[26]  J. Haines,et al.  Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives , 1995, Annals of neurology.

[27]  E. Perry,et al.  A cholinergic connection between normal aging and senile dementia in the human hippocampus , 1977, Neuroscience Letters.

[28]  S. Gauthier,et al.  Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats , 1993, Neuroscience.

[29]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[30]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[31]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[32]  S. Udenfriend,et al.  Expression cloning of a Na(+)-independent neutral amino acid transporter from rat kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.